Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 4, 2025

Figure 4 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes

View Full Paper
Ask AI
Bookmark
Share

Authors

DMDimitrios MathiosNNNoushin NiknafsAAAkshaya V. Annapragada

Discussion

Loading...

Member takes

Overview

Analysis shows high analytical specificity of the ARTEMIS–DELFI approach in detecting HGG mutations, suggesting effective cancer screening.

Key Points

  • The ARTEMIS–DELFI approach demonstrates 90% specificity in detecting high-grade gliomas (HGGs) using cfDNA.
  • Tumor-informed mutation panel assays show an analytical specificity of 99.9%, indicating reliable detection methods.
  • Shorter cfDNA fragments are associated with tumor-specific mutations compared to non-tumor fragments, highlighting their significance.
  • Findings advance our understanding of utilizing cfDNA fragmentation in brain cancer diagnostics, potentially improving patient outcomes.

Cite This Study

Mathios et al. (2025) studied this question.

synapsesocial.com/papers/689a0f86e6551bb0af8d0943https://doi.org/10.1158/2159-8290.29819629
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Figure 5 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes2025
  2. 2Figure 1 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes2025 · 1 citations
  3. 3Figure 2 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes2025
  4. 4Supplementary Figures S1-S10 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes2025
  5. 5Figure 3 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes2025